Why did compounded tirzepatide exist in the first place?
Tirzepatide — the active molecule in Eli Lilly’s branded products Mounjaro and Zepbound — was placed on the FDA drug shortage list because commercial supply could not keep up with the surge in prescriptions that followed approval. Under federal law, when an FDA-approved drug is on the shortage list, licensed compounding pharmacies gain expanded authority to compound that drug for patient-specific needs.
This created a legal window during which 503A compounding pharmacies (those that prepare individual prescriptions) and 503B outsourcing facilities (those that produce larger batches) could compound tirzepatide. The market for compounded tirzepatide grew substantially during this period, as patients found it more accessible — and sometimes more affordable — than the branded version.
What did the FDA actually decide about compounded tirzepatide in late 2024?
In late 2024, the FDA determined that the tirzepatide shortage had been resolved — meaning Eli Lilly had sufficiently increased supply to meet national demand. Under the statutory framework that governs compounding, the shortage-based authorization for compounding tirzepatide then became subject to phase-out.
Specifically, the FDA directed 503B outsourcing facilities to stop producing shortage-based tirzepatide formulations and gave a wind-down period for compliance. The ruling drew more attention for 503B facilities (large-batch producers) than for 503A pharmacies, because 503B compounding had scaled to a size that represented a direct commercial threat to the branded product.
The media and social-media framing — “compound tirzepatide is banned” — overstated the ruling. What actually ended was the blanket shortage-based authorization for 503B bulk production. The 503A patient-specific compounding framework remained intact, subject to the standard rules governing that statute.
What ended wasn’t compounded tirzepatide — it was the blanket shortage exemption, not the individual-prescription pathway.
How does 503A compounding still work?
Under 21 U.S.C. §353a, a 503A pharmacy may compound a drug for an identified individual patient based on a valid prescription, provided the compounded product differs in some way from the commercially available product — for example, a different dosage strength, an excluded allergen, or a formulation the commercial product does not offer.
This is a meaningful distinction. A patient who has a documented clinical reason to use a compounded tirzepatide formulation — and whose prescriber provides a valid prescription establishing that clinical basis — can still receive compounded tirzepatide from a 503A pharmacy. The patient-specific prescription pathway was not closed by the shortage-resolution ruling.
What has changed is the evidentiary and documentation standard expected of the prescribing relationship. The shortage window was more permissive. The post-shortage environment places more weight on the individual clinical relationship and the specific rationale for compounding over the commercial product.
What does this mean for patients right now?
If you were receiving compounded tirzepatide through a legitimate 503A pharmacy with a valid prescription and have an ongoing clinical relationship with your prescriber, your access pathway has not been categorically terminated. Whether your specific pharmacy and prescriber relationship meets the current standard is a clinical and legal question — not one this article can answer for your individual situation.
What you should be cautious of:
- Gray-market and overseas vendors: These sources operate outside the FDA oversight framework regardless of shortage status. Purity, sterility, and accurate dosing are unverifiable. The regulatory change does not make these sources more legitimate — it makes the gap between regulated and unregulated sources starker.
- Telehealth platforms that have gone quiet: Some compounding-heavy telehealth platforms scaled rapidly during the shortage window and are now navigating a significantly changed regulatory environment. If your platform has stopped communicating or become harder to reach, that is a signal to evaluate your options.
- Misleading “still legal” marketing: Vendors who confidently claim full access with no caveats, and no explanation of the compounding basis for that access, deserve skepticism. The regulatory landscape is genuinely nuanced, and blanket “nothing has changed” claims are not supported by the FDA’s public guidance.
PepScribe’s approach: USA 503A compounding only
PepScribe uses licensed 503A compounding pharmacies based in the United States for all tirzepatide prescriptions. Our pharmacy partners compound patient-specific formulations under state pharmacy board oversight and USP quality standards.
We do not use 503B outsourcing facilities for tirzepatide. We do not source from overseas suppliers or gray-market vendors. No hidden overseas supply chain — that is not a marketing phrase for us, it is the operational standard we hold our pharmacy partners to.
Every tirzepatide prescription through PepScribe is issued by a licensed clinician following a clinical review of your intake information. The compounding authorization rests on that prescriber-patient relationship and the clinical rationale it establishes — not on shortage status.
Frequently asked questions
Is compound tirzepatide banned in the US?
The FDA declared the tirzepatide shortage resolved in late 2024 and directed 503A pharmacies to stop compounding tirzepatide based on shortage status. That ruling created significant confusion. However, 503A pharmacies may still compound tirzepatide on a patient-specific basis for patients with documented clinical needs that the commercial product does not meet, such as specific dosage strengths, allergen exclusions, or supply access constraints. The situation is nuanced — access depends on the specific compounding arrangement, not a blanket nationwide ban.
Can I still get compounded tirzepatide?
Compounded tirzepatide remains available through licensed 503A pharmacies for patient-specific prescriptions. What changed is that compounding solely on the basis of the FDA-declared shortage is no longer permitted. Legitimate compounding pharmacies that operate within the 503A framework continue to fill tirzepatide prescriptions for patients whose prescribers have established a clinical rationale.
What is the difference between 503A and 503B compounding for tirzepatide?
503A pharmacies compound individual prescriptions for specific patients under a prescriber-patient relationship. 503B outsourcing facilities produce larger batches for broader distribution and are FDA-registered. The FDA ruling that restricted tirzepatide compounding focused on shortage-based 503B bulk production. 503A patient-specific compounding operates under a different statutory framework.
Should I be worried that tirzepatide compounding will be fully blocked?
The regulatory landscape for compounded GLP-1 drugs continues to evolve. The most responsible approach is to work with a licensed clinician and a pharmacy partner that operates squarely within 503A statutory requirements. Avoid "peptide vendor" websites and gray-market sources, which carry meaningful purity, sterility, and legal risk regardless of how the FDA shortage ruling evolves.
Does the shortage ruling affect branded Mounjaro or Zepbound?
No. The FDA shortage ruling and subsequent compounding restrictions apply to compounding pharmacies, not to the branded products Mounjaro (for type 2 diabetes management) and Zepbound (for chronic weight management), which are FDA-approved and commercially distributed through standard pharmacy channels.